Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0

作者：

Jun Guo

Jie Jin

Mototsugu Oya

Hirotsugu Uemura

Shunji Takahashi

Katsunori Tatsugami

Sun Young Rha

Jae-Lyun Lee

Jinsoo Chung

Ho Yeong Lim

Hsi Chin Wu

Yen Hwa Chang

Arun Azad

Ian D. Davis

Marlene J. Carrasco-Alfonso

Bhupinder Nanua

Jackie Han

Qasim Ahmad

Robert Motzer

机构：

[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma

[2] Peking University First Hospital,Department of Urology

[3] Keio University School of Medicine,Department of Urology

[4] Kindai University Faculty of Medicine,Department of Urology

[5] Cancer Institute Hospital,Department of Medical Oncology

[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences

[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center

[8] Yonsei Cancer Center,Department of Urology

[9] Yonsei University College of Medicine,Division of Hematology

[10] University of Ulsan College of Medicine,Oncology

[11] Center for Prostate Cancer,Department of Urology

[12] National Cancer Center,Division of Urology, Department of Surgery

[13] Samsung Medical Center,Department of Medicine

[14] Sungkyunkwan University,Department of Medicine

[15] China Medical University Hospital,undefined

[16] Taipei Veterans General Hospital,undefined

[17] Monash University,undefined

[18] Monash University,undefined

[19] Eastern Health Clinical School,undefined

[20] Novartis Pharmaceuticals Corporation,undefined

[21] Novartis Pharmaceuticals Corporation,undefined

[22] Genitourinary Oncology Service,undefined

[23] Memorial Sloan-Kettering Cancer Center,undefined

来源：

Journal of Hematology & Oncology | / 11卷

关键词：

Renal cell carcinoma; Pazopanib; Sunitinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
Park, Seong Joon
Lee, Jae-Lyun
Park, Inkeun
Park, Kwonoh
Ahn, Yongcheol
Ahn, Jin-Hee
Lee, Dae-Ho
Ahn, Shin
Song, Cheryn
Hong, Jun Hyuk
Kim, Choung-Soo
Ahn, Hanjong
CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
[22] Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
Rha, Sun Young
Choueiri, Toni K.
Matveev, Vsevolod B.
Alyasova, Anna
Hong, Sung-Hoo
Gordoa, Teresa Alonso
Gurney, Howard
Bjarnason, Georg A.
Buchler, Tomas
Pedrazzoli, Paolo
Takagi, Toshio
Park, Se Hoon
Lee, Jae Lyun
Perini, Rodolfo F.
He, Cixin S. S.
McKenzie, Jodi A.
Eto, Masatoshi
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (06) : 1241 - 1250
[23] Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
Qin, Shukui
Bi, Feng
Jin, Jie
Cheng, Ying
Guo, Jun
Ren, Xiubao
Huang, Yiran
Tarazi, Jamal
Tang, Jie
Chen, Connie
Kim, Sinil
Ye, Dingwei
ONCOTARGETS AND THERAPY, 2015, 8 : 1363 - 1373
[24] Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Vogelzang, Nicholas J.
Pal, Sumanta K.
Ghate, Sameer R.
Swallow, Elyse
Li, Nanxin
Peeples, Miranda
Zichlin, Miriam L.
Meiselbach, Mark K.
Perez, Jose Ricardo
Agarwal, Neeraj
ADVANCES IN THERAPY, 2017, 34 (11) : 2452 - 2465
[25] Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Nicholas J. Vogelzang
Sumanta K. Pal
Sameer R. Ghate
Elyse Swallow
Nanxin Li
Miranda Peeples
Miriam L. Zichlin
Mark K. Meiselbach
Jose Ricardo Perez
Neeraj Agarwal
Advances in Therapy, 2017, 34 : 2452 - 2465
[26] Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Ueda, Takeshi
Uemura, Hirotsugu
Tomita, Yoshihiko
Tsukamoto, Taiji
Kanayama, Hiroomi
Shinohara, Nobuo
Tarazi, Jamal
Chen, Connie
Kim, Sinil
Ozono, Seiichiro
Naito, Seiji
Akaza, Hideyuki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (06) : 616 - 628
[27] Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
Sheng, Xinan
Chi, Zhihong
Cui, Chuanliang
Si, Lu
Li, Siming
Tang, Bixia
Mao, Lili
Lian, Bin
Wang, Xuan
Yan, Xieqiao
Guo, Jun
ONCOTARGET, 2016, 7 (19) : 27044 - 27054
[28] Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Tannir, Nizar M.
Jonasch, Eric
Albiges, Laurence
Altinmakas, Emre
Ng, Chaan S.
Matin, Surena F.
Wang, Xuemei
Wang, Xuemei
Qiao, Wei
Lim, Zita Dubauskas
Tamboli, Pheroze
Rao, Priya
Sircar, Kanishka
Karam, Jose A.
McDermott, David F.
Wood, Christopher G.
Choueiri, Toni K.
EUROPEAN UROLOGY, 2016, 69 (05) : 866 - 874
[29] Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma
Barrios, Carlos H.
Herchenhorn, Daniel
Chacon, Matias
Cabrera-Galeana, Paula
Sajben, Peter
Zhang, Ke
ONCOTARGETS AND THERAPY, 2016, 9 : 5839 - 5845
[30] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial
Xie, Mian
He, Chao Sheng
Huang, Jin Kun
Lin, Qi Zhan
EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 595 - 603

← 1 2 3 4 5 →